Kairos Pharma Ltd. (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer. The analysis revealed a statistically significant difference in progression-free survival (PFS), with a median PFS of 17.7 months for patients receiving ENV-105 plus apalutamide compared to two months for those receiving apalutamide alone (P=0.0008). This strong result suggests that adding ENV-105 to standard therapy may substantially delay disease progression in this difficult-to-treat population.
In response to the data, Kairos Pharma has modified the Phase 2 protocol to enroll patients earlier in disease progression. Patients who experience a prostate-specific antigen (PSA) increase following upfront treatment with an androgen signaling inhibitor will now be randomized to receive either enzalutamide alone or enzalutamide in combination with ENV-105. The company stated that this change is intended to expand the eligible patient population and facilitate enrollment, with completion of the Phase 2 trial targeted in or before the fourth quarter of 2027.
ENV-105 is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. The interim data not only validate this mechanism but also highlight the potential of ENV-105 to become a cornerstone in overcoming treatment resistance in prostate cancer and possibly other malignancies.
The implications of this announcement extend beyond Kairos Pharma. For patients with metastatic castration-resistant prostate cancer, the combination therapy could offer a significantly longer period before disease progression, translating into more time with quality of life and delayed need for subsequent treatments. For the pharmaceutical industry, the results underscore the value of targeting resistance mechanisms, potentially spurring further investment in similar approaches. For investors, the data may boost confidence in Kairos Pharma's pipeline and its ability to bring a differentiated therapy to market.
Kairos Pharma, based in Los Angeles, California, is focused on oncology therapeutics and utilizes structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is at the forefront of this effort. The latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA. To view the full press release, visit https://ibn.fm/EDpxx.
BioMedWire, a specialized communications platform, originally distributed the announcement. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which delivers wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
